x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0012882
| Product Information | |
|---|---|
| Clonality | Monoclonal |
| Isotype | IgG |
| Host Species | Rabbit |
| Reactivity | Human, Mouse, Monkey |
| Applications | WB |
| Product Description | Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Gly129 of human TCF11 protein. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | NFE2L1 |
| UniProt No. | Q14494 |
| Gene ID | 4779 |
| Gene Description | Transcription factor 11 is a basic leucine zipper transcription factor. It is also referred to as Nuclear factor E2-related factor 1. TCF11 was initially reported to activate erythroid-specific, human globin gene expression. It plays an essential role during embryonic development. It also associates with other transcription factors, such as Jun proteins, to transcriptionally control antioxidant response element -mediated expression in response to antioxidants and xenobiotics. TCF11 has been shown to regulate proteasomal degradation and mediate the proteasome recovery pathway after proteasome inhibition. TCF11 is ubiquitously expressed and several isoforms have been reported. The 120 kDa form exists in the endoplasmic reticulum membrane under normal conditions. Upon proteasome inhibition, TCF11 translocates to the nucleus. The 65 kDa N-terminal-truncated form is constitutively localized to the nucleus. TCF11 protein levels are regulated by ubiquitination and proteasomal-mediated degradation; proteasome inhibitors stabilize TCF11. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
